Accès gratuit
Numéro
Med Sci (Paris)
Volume 31, Numéro 10, Octobre 2015
Page(s) 895 - 903
Section M/S Revues
DOI https://doi.org/10.1051/medsci/20153110016
Publié en ligne 19 octobre 2015
  1. Butcher EC, Picker LJ. Lymphocyte homing and homeostasis. Science 1996 ; 272 : 60–66. [CrossRef] [PubMed]
  2. Briskin M, Winsor-Hines D, Shyjan A, et al. Human mucosal addressin cell adhesion molecule-1 is preferentially expressed in intestinal tract and associated lymphoid tissue. Am J Pathol 1997 ; 151 : 97–110. [PubMed]
  3. Nathan C.. Points of control in inflammation. Nature 2002 ; 420 : 846–852. [CrossRef] [PubMed]
  4. Adams DH, Eksteen B. Aberrant homing of mucosal T cells and extra-intestinal manifestations of inflammatory bowel disease. Nat Rev Immunol 2006 ; 6 : 244–251. [CrossRef] [PubMed]
  5. Rivera-Nieves J, Olson T, Bamias G, et al. L-selectin, alpha 4 beta 1, and alpha 4 beta 7 integrins participate in CD4+ T cell recruitment to chronically inflamed small intestine. J Immunol 2005 ; 174 : 2343–2352. [CrossRef]
  6. Leung-Theung-Long S, Guerder S. Les cellules Th17, une nouvelle population de cellules T CD4 effectrices pro-inflammatoires. Med Sci (Paris) 2008 ; 24 : 972–976. [CrossRef] [EDP Sciences] [PubMed]
  7. Dandekar S, George MD, Baumler AJ. Th17 cells, HIV and the gut mucosal barrier. Curr Opin HIV AIDS 2010 ; 5 : 173–178. [CrossRef] [PubMed]
  8. Feagan BG, Greenberg GR, Wild G, et al. Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin. N Engl J Med 2005 ; 352 : 2499–2507. [CrossRef] [PubMed]
  9. Soler D, Chapman T, Yang LL, et al. The binding specificity and selective antagonism of vedolizumab, an anti-alpha4beta7 integrin therapeutic antibody in development for inflammatory bowel diseases. J Pharmacol Exp Ther 2009 ; 330 : 864–875. [CrossRef] [PubMed]
  10. Yednock TA, Cannon C, Fritz LC, et al. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992 ; 356 : 63–66. [CrossRef] [PubMed]
  11. Hesterberg PE, Winsor-Hines D, Briskin MJ, et al. Rapid resolution of chronic colitis in the cotton-top tamarin with an antibody to a gut-homing integrin alpha 4 beta 7. Gastroenterology 1996 ; 111 : 1373–1380. [CrossRef] [PubMed]
  12. Ghosh S, Goldin E, Gordon FH, et al. Natalizumab for active Crohn’s disease. N Engl J Med 2003 ; 348 : 24–32. [CrossRef] [PubMed]
  13. Targan SR, Feagan BG, Fedorak RN, et al. Natalizumab for the treatment of active Crohn’s disease: results of the ENCORE Trial. Gastroenterology 2007 ; 132 : 1672–1683. [CrossRef] [PubMed]
  14. Sandborn WJ, Colombel JF, Enns R, et al. Natalizumab induction and maintenance therapy for Crohn’s disease. N Engl J Med 2005 ; 353 : 1912–1925. [CrossRef] [PubMed]
  15. Louapre C, Maillart E, Papeix C, Lubetzki C. Nouveautés thérapeutiques et stratégies émergentes dans la sclérose en plaques. Med Sci (Paris) 2013 ; 29 : 1105–1110. [CrossRef] [EDP Sciences] [PubMed]
  16. Takazoe M, Watanabe M, Kawaguchi T, et al. S1066 oral alpha-4 integrin inhibitor (AJM300) in patients with active Crohn’s disease: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2009 ; 136 : A-181. [CrossRef]
  17. Stefanich EG, Danilenko DM, Wang H, et al. A humanized monoclonal antibody targeting the beta7 integrin selectively blocks intestinal homing of T lymphocytes. Br J Pharmacol 2011 ; 162 : 1855–1870. [CrossRef] [PubMed]
  18. Rutgeerts PJ, Fedorak RN, Hommes DW, et al. A randomised phase I study of etrolizumab (rhuMAb beta7) in moderate to severe ulcerative colitis. Gut 2013 ; 62 : 1122–1130. [CrossRef] [PubMed]
  19. Vermeire S, O’Byrne S, Keir M, et al. Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial. Lancet 2014 ; 384 : 309–318. [CrossRef] [PubMed]
  20. Vermeire S, Ghosh S, Panes J, et al. The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study. Gut 2011 ; 60 : 1068–1075. [CrossRef] [PubMed]
  21. Haase AT. Targeting early infection to prevent HIV-1 mucosal transmission. Nature 2010 ; 464 : 217–223. [CrossRef] [PubMed]
  22. Haase AT. Early events in sexual transmission of HIV and SIV and opportunities for interventions. Annu Rev Med 2011 ; 62 : 127–139. [CrossRef] [PubMed]
  23. Kader M, Wang X, Piatak M, et al. Alpha4+beta7(hi)CD4+ memory T cells harbor most Th-17 cells and are preferentially infected during acute SIV infection. Mucosal Immunol 2009 ; 2 : 439–449. [CrossRef] [PubMed]
  24. Kelly KA, Wiley D, Wiesmeier E, et al. The combination of the gastrointestinal integrin (alpha4beta7) and selectin ligand enhances T-cell migration to the reproductive tract during infection with Chlamydia trachomatis. Am J Reprod Immunol 2009 ; 61 : 446–452. [CrossRef]
  25. Farstad IN, Halstensen TS, Lien B, et al. Distribution of beta 7 integrins in human intestinal mucosa and organized gut-associated lymphoid tissue. Immunology 1996 ; 89 : 227–237. [CrossRef] [PubMed]
  26. Cicala C, Martinelli E, McNally JP, et al. The integrin alpha4beta7 forms a complex with cell-surface CD4 and defines a T-cell subset that is highly susceptible to infection by HIV-1. Proc Natl Acad Sci USA 2009 ; 106 : 20877–20882. [CrossRef] [PubMed]
  27. Reeves RK, Evans TI, Gillis J, Johnson RP. Simian immunodeficiency virus infection induces expansion of alpha4beta7+ and cytotoxic CD56+ NK cells. J Virol 2010 ; 84 : 8959–8963. [CrossRef] [PubMed]
  28. Wang X, Xu H, Gill AF, et al. Monitoring alpha4beta7 integrin expression on circulating CD4+ T cells as a surrogate marker for tracking intestinal CD4+ T-cell loss in SIV infection. Mucosal Immunol 2009 ; 2 : 518–526. [CrossRef] [PubMed]
  29. Hartigan-O’Connor DJ, Abel K, Van Rompay KK, et al. SIV replication in the infected Rhesus macaque is limited by the size of the preexisting TH17 cell compartment. Sci Transl Med 2012 ; 4 : 136ra169.
  30. Mavigner M, Cazabat M, Dubois M, et al. Altered CD4+ T cell homing to the gut impairs mucosal immune reconstitution in treated HIV-infected individuals. J Clin Invest 2012 ; 122 : 62–69. [CrossRef] [PubMed]
  31. Brenchley JM, Paiardini M, Knox KS, et al. Differential Th17 CD4 T-cell depletion in pathogenic and nonpathogenic lentiviral infections. Blood 2008 ; 112 : 2826–2835. [CrossRef] [PubMed]
  32. Kinter AL, Hennessey M, Bell A, et al. CD25+CD4+ regulatory T cells from the peripheral blood of asymptomatic HIV-infected individuals regulate CD4+ and CD8+ HIV-specific T cell immune responses in vitro and are associated with favorable clinical markers of disease status. J Exp Med 2004 ; 200 : 331–343. [CrossRef] [PubMed]
  33. Schulze Zur Wiesch J, Thomssen A, Hartjen P, et al. Comprehensive analysis of frequency and phenotype of T regulatory cells in HIV infection: CD39 expression of FoxP3+ T regulatory cells correlates with progressive disease. J Virol 2011 ; 85 : 1287–1297. [CrossRef] [PubMed]
  34. Arthos J, Cicala C, Martinelli E, et al. HIV-1 envelope protein binds to and signals through integrin alpha4beta7, the gut mucosal homing receptor for peripheral T cells. Nat Immunol 2008 ; 9 : 301–309. [CrossRef] [PubMed]
  35. Budde ML, Lhost JJ, Dudley DM, et al. Integrin alpha4beta7 is downregulated on the surfaces of simian immunodeficiency virus SIVmac239-infected cells. J Virol 2010 ; 84 : 6344–6351. [CrossRef] [PubMed]
  36. Nawaz F, Cicala C, Van Ryk D, et al. The genotype of early-transmitting HIV gp120s promotes alpha(4)beta(7)-reactivity, revealing alpha(4)beta(7)/CD4 T cells as key targets in mucosal transmission. PLoS Pathog 2011 ; 7 : e1001301. [CrossRef] [PubMed]
  37. Liu J, Bartesaghi A, Borgnia MJ, et al. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008 ; 455 : 109–113. [CrossRef] [PubMed]
  38. Tjomsland V, Ellegard R, Che K, et al. Complement opsonization of HIV-1 enhances the uptake by dendritic cells and involves the endocytic lectin and integrin receptor families. PLoS One 2011 ; 6 : e23542. [CrossRef] [PubMed]
  39. Ansari AA, Reimann KA, Mayne AE, et al. Blocking of alpha4beta7 gut-homing integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J Immunol 2011 ; 186 : 1044–1059. [CrossRef]
  40. Pauls E, Ballana E, Moncunill G, et al. Evaluation of the anti-HIV activity of natalizumab, an antibody against integrin alpha4. AIDS 2009 ; 23 : 266–268. [CrossRef] [PubMed]
  41. Parrish NF, Wilen CB, Banks LB, et al. Transmitted/founder and chronic subtype C HIV-1 use CD4 and CCR5 receptors with equal efficiency and are not inhibited by blocking the integrin alpha4beta7. PLoS Pathog 2012 ; 8 : e1002686. [CrossRef] [PubMed]
  42. Cicala C, Arthos J, Fauci AS. HIV-1 envelope, integrins and co-receptor use in mucosal transmission of HIV. J Transl Med 2011 ; 9 (suppl 1) : S2. [CrossRef] [PubMed]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.